Literature DB >> 24522196

Interferon lambda 3 rs12979860 polymorphism in patients with haemophilia and HCV infection: a predictor of spontaneous viral clearance and sustained virological response.

Maria Elisa Mancuso1, Silvia Linari, Alessio Aghemo, Dario Bartolozzi, Elena Santagostino, Maria Grazia Rumi, Elisa Fognani, Maria Rosaria Fasulo, Laura Gragnani, Raffaele Bruno, Massimo Morfini, Anna Linda Zignego, Massimo Colombo.   

Abstract

Chronic hepatitis C is the main cause of morbidity and mortality in adult haemophilic patients who received non-virally inactivated plasma-derived clotting factor concentrates. Overall, spontaneous viral clearance rate is 10-25% and the only approach that can halt disease progression is hepatitis C virus (HCV) eradication by means of antiviral therapy. In non-haemophilic patients a single nucleotide polymorphism located upstream the gene of interferon lambda 3 (IFNλ3) has been associated with both spontaneous viral clearance and sustained virological response after antiviral treatment. The aim of this study was to assess whether the rs12979860 polymorphism was a predictor of spontaneous viral clearance and of sustained virological response after antiviral therapy in a large cohort of haemophilic patients with HCV infection. The rs12979860 polymorphism, defined as CC genotype or T allele, was tested in a cohort of 342 haemophilic patients and evaluated as predictor of spontaneous clearance or response to antiviral therapy. By multivariate regression analysis the IFNλ3 CC genotype was an independent predictor of spontaneous viral clearance (odds ratio: 3.7, 95% confidence interval: 2.0-6.8). Sustained virological response rates were doubled in patients with the CC genotype than in those with the T allele (78% vs 44%; p<0.001), especially in patients with HCV type 1 (67% vs 32%; p<0.001) and higher sustained response rates were observed in patients with the CC genotype who did not achieve rapid virological response (61% vs 30% in T allele patients; p=0.006).

Entities:  

Keywords:  Haemophilia; antiviral therapy; chronic hepatitis C; interferon lambda 3; spontaneous clearance

Mesh:

Substances:

Year:  2014        PMID: 24522196     DOI: 10.1160/TH13-11-897

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  4 in total

1.  Impact of IFNL4 rs12979860 and rs8099917 polymorphisms on response to Peg-Interferon-α and Ribavirin in patients with congenital bleeding disorder and chronic hepatitis C.

Authors:  Maryam Keshvari; Seyed Moayed Alavian; Bita Behnava; Ali Pouryasin; Johanna C Craig; Heidar Sharafi
Journal:  J Clin Lab Anal       Date:  2016-10-13       Impact factor: 2.352

2.  Possible relationship between IL28B rs12979860 and TLR2 -196 to -174 del/ins polymorphisms and the liver fibrosis stage in hepatitis C patients.

Authors:  Zehra Öksüz; Enver Üçbilek; Mehmet Sami Serin; Serkan Yaraş; Gülhan Örekici Temel; Orhan Sezgin
Journal:  Arch Virol       Date:  2021-11-24       Impact factor: 2.574

3.  The interferon lambda 4 rs368234815 predicts treatment response to pegylated-interferon alpha and ribavirin in hemophilic patients with chronic hepatitis C.

Authors:  Maryam Keshvari; Seyed Moayed Alavian; Bita Behnava; Ali Pouryasin; Heidar Sharafi
Journal:  J Res Med Sci       Date:  2016-09-01       Impact factor: 1.852

4.  HCV-related liver and lymphoproliferative diseases: association with polymorphisms of IL28B and TLR2.

Authors:  Valli De Re; Mariangela De Zorzi; Laura Caggiari; Gianfranco Lauletta; Maria Lina Tornesello; Elisa Fognani; Marta Miorin; Vito Racanelli; Luca Quartuccio; Laura Gragnani; Sabino Russi; Fabio Pavone; Michela Ghersetti; Elena Garlatti Costa; Pietro Casarin; Riccardo Bomben; Cesare Mazzaro; Giancarlo Basaglia; Massimiliano Berretta; Emanuela Vaccher; Francesco Izzo; Franco Maria Buonaguro; Salvatore De Vita; Anna Linda Zignego; Paolo De Paoli; Riccardo Dolcetti
Journal:  Oncotarget       Date:  2016-06-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.